


Coming Attractions

Drug	Category	Sponsor	Cancer Indication	Phase of Development	Comments
ipilimumab (MDX-010)	Human monoclonal antibody	Bristol-Myers Squibb Company Princeton, NJ Medarex, Inc. Princeton, NJ	Metastatic Melanoma	Phase III for more info call 212-546-4000 609-430-2880	Known as anti-CTLA 4, fast track designated by the FDA, this antibody binds to a molecule on T-Cells playing a critical role in regulating natural immune responses.
FavId	Immunotherapy vaccine	Favrille, Inc. San Diego, CA	B-cell non-Hodgkin's lymphoma	Phase III for more info call 800-870-0084	Active Cellular Immunotherapy. Personalized medicine at its best, fast track designated by the FDA, primary endpoint analysis expected this year.
lapuleucel-T (Neuvence)	Immunotherapy vaccine	Dendreon Corporation Seattle, WA	Metastatic Breast Cancer	Phase I for more info call 206-256-4545	Active Cellular Immunotherapy. Two Phase 1 clinical trials for treating patients with breast, ovarian and colorectal solid tumors expressing HER2/neu have been completed.
ANX-510 (CoFactor)	biomodulator	Adventrx Pharmaceuticals San Diego, CA	Metastatic Colorectal Cancer	Phase III for more info call 858-552-0866 Ext.236	Fast track designated by the FDA, designed to replace leucovorin to enhance activity and reduce toxicity

★ We realize that there are many drugs in research and development. The ones listed above are a select few that have been chosen as potential coming attractions.

Nurstoons

by Carl Elbing



www.nurtoon.com